source
- Pharvaris reports 83% drop in hereditary angioedema attacks in phase 3 trial, FDA decision pendingPharvaris announced that its oral bradykinin B2 receptor antagonist, deucrictibant, met the primary goal in a second phase 3 study. The trial, called CHAPTER-3, enrolled 85 patients with three for…
- Novartis' del-desiran fails primary endpoint in phase 3 Harbor trial for myotonic dystrophy type 1Novartis announced that its experimental therapy del-desiran did not meet the primary endpoint in the phase 3 Harbor trial, which evaluated improvement in video hand opening time in patients with m…Fierce Biotech · 2mo agoNegative readoutNegative